Effects of Multisensory Home-based Programme on Psychological Well-being and Laboratory Outcomes among People with Metabolic Syndrome in Community

Phase 2

Recruiting

• Conditions: Metabolic syndrome (MetS); Metabolic syndrome, multisensory based programme, psychological well-being, occupational therapy

• Registration Number: TCTR20240401007
• Lead Sponsor: Faculty of Associated Medical Sciences, Chaing Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-01
• Study Completion: 2024-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. people who have three or more of the risk factors as defined by Harmonized criteria of MetS (Alberti et al., 2009), including elevated FPG at least 100 mg/dL or drug treatment of elevated glucose, elevated BP at least 130/85 mmHg or antihypertensive drug treatment, reduced HDL-C less than 40 mg/dL in male or 50 mg/dL in female or drug treatment for reduced HDL-C, elevated at least TG 150 mg/dL or drug treatment for elevated triglycerides, or WC at least 90 cm in male, at least 80 cm in female, 2. People who live in Nam Phrae sub-district, Hang Dong District, Chiang-Mai Province, 3. People with moderate to very high levels of stress as screened by using the Srithanya stress scale, 4. People who can communicate in the Thai language, 5. People who is willing to participate in this study and agree to sign an informed consent form

Exclusion Criteria

1. People who have been diagnosed with sensory impairment by a physician, 2.People who have been diagnosed with thyroid, respiratory, liver, kidney, or cardiovascular diseases by a physician, 3. People with history of serious mental illness, including depression, schizophrenia, bipolar disorder, anxiety disorder, and other psychotic disorders, 4. People with cognitive impairment, 5. People who receive drug treatment that will affect cortisol levels, including cushing drugs, antidepressant, antipsychotic, anti-anxiety, dopamine agents, opiod or antiopioids, drugs of abuse, hormones, rosiglitazone and pioglitazone

Study & Design

• Study Type: Interventional
• Study Design: Not specified